Get the Stockscreener App
9.88
4.45%
-0.46
After Hours:
10.07
0.19
+1.92%
Upstream Bio Inc stock is traded at $9.88, with a volume of 552.12K.
It is down -4.45% in the last 24 hours and up +7.04% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$10.34
Open:
$10.4
24h Volume:
552.12K
Relative Volume:
0.44
Market Cap:
$537.67M
Revenue:
$2.85M
Net Income/Loss:
$-143.44M
P/E Ratio:
-3.7098
EPS:
-2.6632
Net Cash Flow:
$-133.44M
1W Performance:
+0.41%
1M Performance:
+7.04%
6M Performance:
-54.45%
1Y Performance:
+27.16%
1-Day Range:
$9.79
$10.52
1-Week Range:
$9.63
$10.67
52-Week Range:
$7.25
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
9.88 | 562.70M | 2.85M | -143.44M | -133.44M | -2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Bull Bear: Is Upstream Bio Inc a cyclical or defensive stock2026 Intraday Action & Low Drawdown Trading Strategies - baoquankhu1.vn
UPB Options Volatility — NASDAQ:UPB - TradingView — Track All Markets
UPB Options Chain — NASDAQ:UPB - TradingView — Track All Markets
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward - TipRanks
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Earnings Update: Is Upstream Bio Inc still a buy after recent gains2026 Rallies & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Truist cuts Upstream Bio stock price target on trial timeline By Investing.com - Investing.com Canada
Market Recap: Is Upstream Bio Inc forming a bullish divergence2026 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Upstream Bio, Inc. (UPB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Retail Surge: Does Upstream Bio Inc have a sustainable dividendTrade Signal Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
UpStream Bio | 10-K: FY2025 Annual Report - Moomoo
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors - TipRanks
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line - MarketBeat
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $15 to $42 - moomoo.com
Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts - Investing.com India
Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts By Investing.com - Investing.com South Africa
Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40 - marketscreener.com
Upstream Bio, Inc. Enters At-the-Market Sales Agreement with Leerink Partners LLC for Common Stock Offering - Minichart
Upstream Bio Announces Positive Phase 2 Results and Phase 3 Strategy for Verekitug in Severe Asthma and CRSwNP, Financials Support Operations Through 2027 - Minichart
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027 By Investing.com - Investing.com South Africa
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027 - Investing.com India
According to the latest filing with the SEC, biotechnology company Upstream Bio Inc has entered into a sales agreement with Leerink Partners LLC and plans to raise up to 150 millions dollars by publicly offering common shares. - Bitget
Upstream Bio enters $150 million at-the-market sales agreement with Leerink Partners - Investing.com
Upstream Bio Launches $150 Million At-The-Market Program - TipRanks
Upstream Bio (NASDAQ: UPB) files ATM to raise up to $150M via Leerink - Stock Titan
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
Upstream Bio (NASDAQ: UPB) advances verekitug for severe asthma, CRSwNP and COPD - stocktitan.net
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors - TipRanks
Why Is Upstream Bio Stock Trading Higher Today?Upstream Bio (NASDAQ:UPB) - Benzinga
Will Upstream Bio Inc outperform during market ralliesQuarterly Growth Report & AI Forecasted Stock Moves - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Upstream Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
UPB: Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027 - TradingView
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug - tradersunion.com
Upstream Bio Q4 net loss widens on higher R&D costs - TradingView
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Upstream Bio (NASDAQ:UPB) Trading Up 11.2%What's Next? - MarketBeat
Gainers Report: Is Upstream Bio Inc still a buy after recent gains2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Aug EndMonth: What is the next catalyst for Upstream Bio IncMarket Trend Report & Stock Timing and Entry Methods - baoquankhu1.vn
UPB SEC FilingsUpStream Bio Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Upstream Bio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares By Investing.com - Investing.com India
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):